California Stem Cell, Inc. (CSC), an Irvine, California-based stem cell research and drug discovery company, announced that it has completed a Series B financing round with private investors.
The financing will enable the company to support the advancement of its therapeutic products to human clinical trials, as well as the generation and distribution of its tools to aid in stem cell research and drug discovery.
Founded in 2005, CSC develops proprietary therapeutic products to treat several neurodegenerative diseases, as well as innovative stem cell-based human cell products to facilitate research and conventional drug discovery.
The company is currently in the pre-clinical development stage of stem cell-derived therapies for spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and spinal cord injury.
FinSMEs
21/12/2009